

Characterization of nanoparticles by continuous contrast variation in SAXS

vorgelegt von
Master-Physiker
Raul Garcia Diez
geboren in Barcelona, Spanien

Von der Fakultät II - Mathematik und Naturwissenschaften
der Technischen Universität Berlin
zur Erlangung des akademischen Grades
Doktor der Naturwissenschaften
Dr. rer. nat.

genehmigte Dissertation

Promotionsausschuss:

Vorsitzender: Prof. Dr. XXX

Gutachter: Prof. Dr. Stefan Eisebitt

Gutachterin: Prof. Dr. Simone Raoux

Gutachter: Prof. Dr. Mathias Richter

Tag der wissenschaftlichen Aussprache:

Berlin 2016

1

Introduction

In 1966, Richard Fleischer directed *Fantastic Voyage*, a film about the voyage of a miniaturized submarine used to cruise along human blood vessels and repair the damaged caused to the scientist's brain by a blood clot. The idea of treating from the inside damaged cells or organs fuelled the imagination of the next generation scientists and shaped the incipient field of nanomedicine. Less than 30 years later, science fiction became science fact and Doxil was approved by the US Food and Drug Administration in 1995 as the first nanodrug commercially available (Barenholz, 2012). Although 20 years after this milestone nano-submarines are still a long way off, nanomedicine is a well-established research field and dozens of products are under clinical trials or have been approved by the relevant health agencies.

The precursor to the nanomedicine breakthrough can be found in the tremendous progress in nanoparticles research observed in the 60s and 70s of the last century. Nanoparticles (NPs) are objects with *one or more external dimensions in the size range from 1 nm to 100 nm* (European Commission Recommendation for nanomaterial (2011/696/EU)) and have a preeminent position in the continuously growing world of nanotechnology, employed as paints or cosmetic products (Guterres *et al.*, 2007). Besides, the application of NPs in the emerging field of nanomedicine opens up exciting prospects (Nie *et al.*, 2007; Sahoo & Labhasetwar, 2003; Wickline & Lanza, 2003; Zhou *et al.*, 2014; Rosen & Abribat, 2005), especially considering their possibilities as platforms for drug-delivery (Wang *et al.*, 2012) or encapsulating imaging agents (Tao *et al.*, 2011).

The development of NPs is currently focused towards tailoring nanodrug carriers with flexible surface functionalisations and controlled morphologies (Euliss *et al.*, 2006; Yang *et al.*, 2005). The morphology of NPs is typically specified by parameters like size, shape, density or chemical composition of the particle, which are fundamental and defining aspects of the particle functions and determine their applicability in real-world medical applications (Vittaz *et al.*, 1996). In this regard, the size of NPs is one of the most crucial physicochemical properties of nanodrugs, because it delimits whether they can intrude into the biological cells or the targeted tumor sites. An accurate and reliable description of the morphological traits of the NPs is therefore of vital importance for their favorable translation into successful nanomaterials.

The term *nanometrology* refers to the science of accurate and correct measurement of relevant properties at the nanometre range. A central concept in metrology is *traceability*, which refers to the ability of relating the measured value i.e. measurand to a base unit definition of the International System of Units (SI system) by an unbroken chain of comparisons with known uncertainties. This enables an objective comparison of the results obtained by different methods based on a consistent uncertainty budget associated to the measurand. The fundamental research in the field of metrology in Germany is addressed by its national metrology institute, the Physikalisch-Technische Bundesanstalt (PTB). Founded in 1887, the PTB is devoted among other metrological activities to the determination of fundamental and natural constants or the technology transfer for the industry.

In the nanoscale level, PTB is involved in the development of the dimensional nanometrology field, which studies the measurement of the physical size or distances of a given nanomaterial and traces it back to the *nm* unit. There are several available techniques which are suitable for the sizing of NPs, though not all provide a traceable measurement. A prime example is dynamic light scattering (DLS), the most widely used tool in nanomedicine (Murphy, 1997; Hallett *et al.*, 1991; Egelhaaf *et al.*, 1996; Takahashi *et al.*, 2008; Jans *et al.*, 2009; Hoo *et al.*, 2008). DLS is well-established and has indisputable advantages in the size characterization of the NPs, e.g. easy-to-use instrumentations, fast and low-cost operation, but it is not capable of a traceable size determination as there is no general relationship between the measured hydrodynamic diameter and the physical size of the NPs (Meli *et al.*, 2012).

Other ensemble techniques extensively used are differential centrifugal sedimentation (DCS) (Fielding *et al.*, 2012) and Nanoparticle Tracking Analysis (NTA), both capable of measuring the NPs in suspension, i.e. in their native medium. While DCS is based on the sedimentation of NPs through a density gradient, NTA is a single-particle counting method that relates the Brownian movement of the particles with the measured laser light scattering. The particle size distribution obtained with DCS is traced down to a calibration standard of known size and density, resulting in a non-traceable measurement. Similarly to DLS, the NTA measurand derives from the hydrodynamic properties of the NPs (REF-Towards traceable size determination of extracellular vesicles).

Microscopic tools are also frequently used for structural investigations (Joensson *et al.*, 1991; Silverstein *et al.*, 1989) and proved to be useful techniques for solid NPs due to their SI traceability achieved by coupling the measurement table with a laser interferometer (Meli *et al.*, 2012). Nevertheless, techniques such as transmission scanning electron microscopy (TSEM) or atomic force microscopy (AFM) are not ensemble averaged and the statistical accuracy of non-ensemble methods is usually not sufficient. Besides, the removal of the original suspending medium can be considered another drawback, as well as the possible distortion of the particle's morphology during the drying process, though it can be partially overcome by cryo-TEM (Li *et al.*, 1998).

The nanoparticles envisioned for medical use tend to be found in the soft matter regime and thus the characterization tools must be carefully chosen considering the measurement limitations. For example, biodegradable NPs, e.g. polymeric colloids, are finding many medical applications, especially as drug-carriers (Kattan *et al.*, 1992; Vicent & Duncan, 2006) and are starting to undergo clinical trials (Patel *et al.*, 2012; Beija *et al.*, 2012; Cabral & Kataoka, 2014). However, the size determination of polymeric NPs with a well-known technique like AFM is rather challenging (REF-Particle deformation induced by AFM tapping under different setpoint voltages) and suggests alternative approaches.

Liposomes are spheric vesicles composed of a closed phospholipid bilayer membrane capable of encapsulating hydrophilic compounds. The importance of lipid vesicles in the progress of nanomedicine is indisputable, as the first approved nanodrug is a liposomal formulation of doxorubicin, Doxil. Nowadays liposomes continue to be a widespread instrument for drug delivery (Pérez-Herrero & Fernández-Medarde, 2015), but their complicate internal structure requires typically more than a single a characterization tool (Khorasani *et al.*, 2014). Likewise, relevant biological structures in nanomedicine possess heterogenous morphologies rather difficult to detect with imaging techniques. For instance, electron microscopy is an effective tool for direct observation of the shape and size distribution of nanoparticles, but it cannot conclusively elucidate their inner composition.

The use of an ensemble-average and non-destructive technique such as small-angle X-ray scattering (SAXS) arises as an appropriate alternative (Leonard Jr *et al.*, 1952; Motzkus, 1959). SAXS can discern electron density differences in the structure of NPs and offers advantages to other methods which require prior treatment of the sample and are not averaging. SAXS is based on the elastic scattering of X-ray photons by the electron density distribution of an object and is traceable down to the SI unit *nm* for the size determination of sufficiently monodisperse NPs (Meli *et al.*, 2012). SAXS has been extensively employed in the characterization of polymeric colloids (Dingenouts *et al.*, 1999; Ballauff, 2011) and its use in liposome research is also ubiquitous. For instance, it has been applied to characterize the lamellarity, bilayer thickness, area per lipid ratio 7–9 and the thickness of the PEG-layer of different liposomal samples 10,11, as well as to describe the influence of extrusion on the average number of bilayers 12 and to determine the electron density profile of liposomes 8,9,13 and biological vesicles 14. **CHECK REFERENCES**

Despite being a highly informative method for the accurate characterization of NPs, the difficulties in the interpretation of the scattering curves in the reciprocal space demands complementary experimental information (Mykhaylyk, 2012). The solvent contrast variation approach is a noteworthy candidate due to the complementary data that can be collected at each independent contrast. The contrast variation method in SAXS varies systematically the electron density of the suspending medium by adding a suitable contrast agent, e.g. sucrose, in order to resolve the different contributions of the particle components to the scattering. By measuring SAXS patterns as a function of the adjusted contrast, a more detailed insight into the particle morphology can be obtained in comparison to single-contrast experiments (Bolze *et al.*, 2004). For instance, the internal structure can be modelled in terms of the radial electron density (Dingenouts *et al.*, 1994a, 1999; Ballauff, 2011; Ballauff *et al.*, 1996) and the individual contribution of each component can be distinguished (Beyer *et al.*, 1990; Grunder *et al.*, 1991, 1993; Ottewill *et al.*, 1995; Bolze *et al.*, 1997; Dingenouts *et al.*, 1994b) as well as its density (Mykhaylyk *et al.*, 2007).

This work proposes a novel approach to solvent contrast variation in SAXS based on the formation of a solvent density gradient within a capillary which enables the acquisition of SAXS patterns at a continuous range of contrasts and, as a result, collect in a relatively short timespan an extensive data set of complementary scattering curves. This intelligent strategy averts the most problematic issues of the classical solvent contrast variation technique, namely the discrete range of available solvent electron densities and the prolonged time required for the preparation of the complementary samples and for the obtention of the experimental data.

1.1 structure of the thesis

In this thesis, an overview of nanoparticles and current nanometrology is given in chapter 1. In chapter 2 Small-Angle X-ray Scattering and its application for the determination of the size of nanoparticles is explained. The tools and instruments used for the measurements carried out in the course of this thesis are described in chapter 3. Chapter 4 details how the measurements and analyses were performed in general. The results for the different samples are presented in chapter 5. Finally, chapter 5.4 comprises a final discussion and the conclusion of this thesis.

Extensive parts of the work presented in Chapters 4 to 6 have been published in peer-reviewed journals.[REF] Annotations in each (sub-)chapter indicate which publications correspond to the presented results.

Large parts of every sub-chapter are published in peer-reviewed journals.
chapter 1 and 2 provides the basis for chapter 3

Bibliography

- BALLAUFF, M. 2011 Analysis of Polymer Colloids by Small-Angle X-Ray and Neutron Scattering: Contrast Variation. *Adv Eng Mater* **13**, 793–802.
- BALLAUFF, M., BOLZE, J., DINGENOUTS, N., HICKL, P. & PÖTSCHKE, D. 1996 Small-angle X-ray scattering on latexes. *Macromol Chem Phys* **197**, 3043–3066.
- BARENHOLZ, Y. C. 2012 Doxil® — The first FDA-approved nano-drug: Lessons learned. *Journal of Controlled Release* **160**, 117–134.
- BEIJA, M., SALVAYRE, R., LAUTH-DE VIGUERIE, N. & MARTY, J.-D. 2012 Colloidal systems for drug delivery: From design to therapy. *Trends Biotechnol* **30**, 485–496.
- BEYER, D., LEBEK, W., HERGETH, W.-D. & SCHMUTZLER, K. 1990 SAXS study of core-shell colloids. *Colloid Polym Sci* **268**, 744–748.
- BOLZE, J., BALLAUFF, M., RISCHE, T., RUDHARDT, D. & MEIXNER, J. 2004 In situ Structural Characterization of Semi-Crystalline Polymer Latex Particles by Small-Angle X-Ray Scattering. *Macromol Chem Phys* **205**, 165–172.
- BOLZE, J., HÖRNER, K. D. & BALLAUFF, M. 1997 Small-angle X-ray scattering analysis of the radial structure of latex particles swollen by a nonpolar monomer. *Langmuir* **13**, 2960–2964.
- CABRAL, H. & KATAOKA, K. 2014 Progress of drug-loaded polymeric micelles into clinical studies. *J Control Release* **190**, 465–476.
- DINGENOUTS, N., BOLZE, J., PÖTSCHKE, D. & BALLAUFF, M. 1999 Analysis of Polymer Latexes by Small-Angle X-Ray Scattering. In *Polymer Latexes - Epoxide Resins - Polyampholytes* (ed. A. Abe), pp. 1–47. Berlin-Heidelberg: Springer Verlag.
- DINGENOUTS, N., KIM, Y.-S. & BALLAUFF, M. 1994a Radial density distribution in core-shell latexes as revealed by small-angle X-ray scattering. *Macromol Rapid Comm* **15**, 613–617.
- DINGENOUTS, N., PULINA, T. & BALLAUFF, M. 1994b Structure of carboxylated latices as revealed by small-angle X-ray scattering. *Macromolecules* **27**, 6133–6136.
- EGELHAAF, S. U., WEHRLI, E., MULLER, M., ADRIAN, M. & SCHURTENBERGER, P. 1996 Determination of the size distribution of lecithin liposomes: A comparative study using freeze fracture, cryoelectron microscopy and dynamic light scattering. *Journal of Microscopy* **184**, 214–228.

- EULISS, L. E., DUPONT, J. A., GRATTON, S. & DESIMONE, J. 2006 Imparting size, shape, and composition control of materials for nanomedicine. *Chem Soc Rev* **35**, 1095.
- FIELDING, L. A., MYKHAYLYK, O. O., ARMES, S. P., FOWLER, P. W., MITTAL, V. & FITZPATRICK, S. 2012 Correcting for a Density Distribution: Particle Size Analysis of Core–Shell Nanocomposite Particles Using Disk Centrifuge Photosedimentometry. *Langmuir* **28**, 2536–2544.
- GRUNDER, R., KIM, Y. S., BALLAUFF, M., KRANZ, D. & MÜLLER, H.-G. 1991 Analysis of Polymer Latices by Small-Angle X-Ray Scattering. *Angew Chem Int Edit* **30**, 1650–1652.
- GRUNDER, R., URBAN, G. & BALLAUFF, M. 1993 Small-angle x-ray analysis of latex particles with core-shell morphology. *Colloid Polym Sci* **271**, 563–572.
- GUTERRES, S. S., ALVES, M. P. & POHLMANN, A. R. 2007 Polymeric Nanoparticles, Nanospheres and Nanocapsules, for Cutaneous Applications. *Drug Target Insights* **2**, 147–157.
- HALLETT, F. R., WATTON, J. & KRYGSMAN, P. 1991 Vesicle sizing. *Biophys J* **59**, 357–362.
- HOO, C. M., STAROSTIN, N., WEST, P. & MECARTNEY, M. L. 2008 A comparison of atomic force microscopy (AFM) and dynamic light scattering (DLS) methods to characterize nanoparticle size distributions. *J Nanopart Res* **10**, 89–96.
- JANS, H., LIU, X., AUSTIN, L., MAES, G. & HUO, Q. 2009 Dynamic Light Scattering as a Powerful Tool for Gold Nanoparticle Bioconjugation and Biomolecular Binding Studies. *Anal. Chem.* **81**, 9425–9432.
- JOENSSON, J. E. L., HASSANDER, H., JANSSON, L. H. & TOERNELL, B. 1991 Morphology of two-phase polystyrene/poly(methyl methacrylate) latex particles prepared under different polymerization conditions. *Macromolecules* **24**, 126–131.
- KATTAN, J., DROZ, J.-P., COUVREUR, P., MARINO, J.-P., BOUTAN-LAROZE, A., ROUGIER, P., BRAULT, P., VRANCKX, H., GROGNET, J.-M., MORGE, X. & SANCHO-GARNIER, H. 1992 Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. *Invest. New Drugs* **10**, 191–199.
- KHORASANI, A. A., WEAVER, J. L. & SALVADOR-MORALES, C. 2014 Closing the gap: Accelerating the translational process in nanomedicine by proposing standardized characterization techniques. *Int J Nanomedicine* **9**, 5729–5751.
- LEONARD JR, B. R., ANDEREGG, J. W., KAESBERG, P. & BEEMAN, W. W. 1952 The Size of Latex Particles by X-Ray Scattering. *J Appl Phys* **23**, 152–152.
- LI, X., HIRSH, D. J., CABRAL-LILLY, D., ZIRKEL, A., GRUNER, S. M., JANOFF, A. S. & PERKINS, W. R. 1998 Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. *Biochimica et Biophysica Acta (BBA) - Biomembranes* **1415**, 23–40.
- MELI, F., KLEIN, T., BUHR, E., FRASE, C. G., GLEBER, G., KRUMREY, M., DUTA, A., DUTA, S., KORPELAINEN, V., BELLOTTI, R., PICOTTO, G. B., BOYD, R. D. & CUENAT, A. 2012 Traceable size determination of nanoparticles, a comparison among European metrology institutes. *Meas. Sci. Technol.* **23**, 125005.

- MOTZKUS, F. 1959 Untersuchung kolloider Systeme auf Partikelgrösse und Polydisperität mit Hilfe der Röntgenkleinwinkelstreuung. *Acta Crystallogr* **12**, 773–786.
- MURPHY, R. M. 1997 Static and dynamic light scattering of biological macromolecules: What can we learn? *Current Opinion in Biotechnology* **8**, 25–30.
- MYKHAYLYK, O. O. 2012 Structural Characterization of Colloidal Core-shell Polymer-based Nanoparticles Using Small-angle X-ray Scattering. In *Proceedings of the International Conference Nanomaterials: Applications and Properties*, p. 01PCN04. Sumy State University Publishing.
- MYKHAYLYK, O. O., RYAN, A. J., TZOKOVA, N. & WILLIAMS, N. 2007 The application of distance distribution functions to structural analysis of core-shell particles. *J Appl Crystallogr* **40**, s506–s511.
- NIE, S., XING, Y., KIM, G. J. & SIMONS, J. W. 2007 Nanotechnology Applications in Cancer. *Annual Review of Biomedical Engineering* **9**, 257–288.
- OTTEWILL, R. H., COLE, S. J. & WATERS, J. A. 1995 Characterization of particle morphology by scattering techniques. *Macromol Symp* **92**, 97–107.
- PATEL, T., ZHOU, J., PIEPMEIER, J. M. & SALTZMAN, W. M. 2012 Polymeric nanoparticles for drug delivery to the central nervous system. *Adv Drug Deliver Rev* **64**, 701–705.
- PÉREZ-HERRERO, E. & FERNÁNDEZ-MEDARDE, A. 2015 Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. *European Journal of Pharmaceutics and Biopharmaceutics* **93**, 52–79.
- ROSEN, H. & ABRIBAT, T. 2005 The rise and rise of drug delivery. *Nat Rev Drug Discov* **4**, 381–385.
- SAHOO, S. K. & LABHASETWAR, V. 2003 Nanotech approaches to drug delivery and imaging. *Drug Discovery Today* **8**, 1112–1120.
- SILVERSTEIN, M. S., TALMON, Y. & NARKIS, M. 1989 Microstructure of polyacrylate/polystyrene two-stage latices. *Polymer* **30**, 416–424.
- TAKAHASHI, K., KATO, H., SAITO, T., MATSUYAMA, S. & KINUGASA, S. 2008 Precise Measurement of the Size of Nanoparticles by Dynamic Light Scattering with Uncertainty Analysis. *Particle & Particle Systems Characterization* **25**, 31–38.
- TAO, L., HU, W., LIU, Y., HUANG, G., SUMER, B. D. & GAO, J. 2011 Shape-specific polymeric nanomedicine: Emerging opportunities and challenges. *Exp Biol Med* **236**, 20–29.
- VICENT, M. J. & DUNCAN, R. 2006 Polymer conjugates: Nanosized medicines for treating cancer. *Trends Biotechnol* **24**, 39–47.
- VITTAZ, M., BAZILE, D., SPENLEHAUER, G., VERRECCHIA, T., VEILLARD, M., PUISIEUX, F. & LABARRE, D. 1996 Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators. *Biomaterials* **17**, 1575–1581.
- WANG, A. Z., LANGER, R. & FAROKHZAD, O. C. 2012 Nanoparticle Delivery of Cancer Drugs. *Annu Rev Med* **63**, 185–198.

- WICKLINE, S. A. & LANZA, G. M. 2003 Nanotechnology for Molecular Imaging and Targeted Therapy. *Circulation* **107**, 1092–1095.
- YANG, Z., HUCK, W. T. S., CLARKE, S. M., TAJBAKHS, A. R. & TERENTJEV, E. M. 2005 Shape-memory nanoparticles from inherently non-spherical polymer colloids. *Nat Mater* **4**, 486–490.
- ZHOU, X., PORTER, A. L., ROBINSON, D. K. R., SHIM, M. S. & GUO, Y. 2014 Nano-enabled drug delivery: A research profile. *Nanomedicine: Nanotechnology, Biology and Medicine* **10**, e889–e896.